GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (STU:BIX) » Definitions » Short Interest

BioInvent International AB (STU:BIX) Short Interest


View and export this data going back to 2013. Start your Free Trial

What is BioInvent International AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of BioInvent International AB's Short Interest

For the Biotechnology subindustry, BioInvent International AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioInvent International AB's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's Short Interest distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's Short Interest falls into.


;
;

BioInvent International AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (STU:BIX) » Definitions » Short Interest
Comparable Companies
OSTO:VICO OSTO:HNSA OSTO:EGTX OSTO:GENO OSTO:XSPRAY OSTO:DMYD B OSTO:SYNACT XSAT:HAMLET B OSTO:SANION OSTO:MAGLE VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
BINV:Sweden 0H22:UK BIX0:Germany
Address
Ideongatan 1, Lund, SWE, SE-223 70
Website
https://www.bioinvent.com
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines